Urology Market by Product Type (Disposable Devices, Reusable Devices), Application (Benign Prostatic Hyperplasia Treatment, Cancer Diagnosis, Stone Removal), End User, Distribution Channel, Technology - Global Forecast 2025-2032
Description
The Urology Market was valued at USD 58.00 billion in 2024 and is projected to grow to USD 64.28 billion in 2025, with a CAGR of 11.62%, reaching USD 139.85 billion by 2032.
Contextual introduction describing how demographic trends, clinical demands, and technological advances are collectively redefining urology care pathways and procurement priorities
Urology practice and device innovation sit at the intersection of demographic pressure, technological evolution, and shifting care delivery models. Recent advances in imaging, minimally invasive instrumentation, and single-use device design have combined with rising procedural volumes to reshape clinical pathways, procurement priorities, and vendor strategies. Clinicians seek tools that improve patient outcomes while supporting faster throughput and lower perioperative risk, whereas procurement leaders prioritize device reliability, reprocessing efficiency, and cost predictability.
Against this backdrop, the landscape is further influenced by policy changes, supply chain restructuring, and evolving reimbursement frameworks that affect how hospitals, ambulatory surgical centers, and clinics evaluate new technologies. These dynamics create both risk and opportunity for manufacturers, distributors, and health systems. Understanding the nuanced interplay between device types, clinical applications, and technology enablers is critical for stakeholders preparing for near-term shifts and for those designing long-term portfolios that emphasize value-based care.
Comprehensive overview of the major structural changes reshaping urology including care-site migration, imaging advances, single-use adoption, and infection control priorities
The last several years have witnessed transformative shifts that have materially altered the urology landscape. First, the move toward ambulatory care and same-day procedures has elevated demand for devices and technologies that support shorter procedure times, reduced inpatient stays, and predictable outcomes. This trend has placed a premium on endoscopic ergonomics, single-use device reliability, and technologies that integrate seamlessly into outpatient workflows.
Second, imaging sophistication and image-guided interventions have progressed rapidly, enabling more precise diagnostics and targeted therapy. Innovations in CT, MRI, and ultrasound imaging are complemented by improved visualization in flexible and rigid endoscopes, which together enhance diagnostic clarity and procedural accuracy. Third, the rapid adoption of laser technology for stone removal and benign prostatic hyperplasia treatment has shifted procedural algorithms, reducing reliance on more invasive approaches and supporting faster recovery.
Finally, heightened attention to infection prevention, supply chain resilience, and lifecycle costs is driving re-evaluation of reusable versus disposable devices. Decision-makers increasingly weigh the clinical benefits of reusable endoscopes and instruments against the operational risks and costs associated with reprocessing, sterilization, and potential device downtime. Overall, these transformative shifts are creating a market environment in which clinical efficacy, operational efficiency, and risk mitigation converge as the primary determinants of adoption.
Strategic analysis of how the United States tariffs enacted in 2025 catalyzed sourcing realignment, procurement negotiation shifts, and supply chain resilience measures across urology stakeholders
The imposition of United States tariffs in 2025 introduced a new layer of complexity across global medical device supply chains and procurement strategies. Tariff-driven cost increases for imported components and finished devices compelled many manufacturers to re-evaluate sourcing footprints, reconsider supplier relationships, and, where feasible, shift assembly and final production closer to end markets. These adjustments affected lead times and inventory management practices, prompting increased reliance on safety stock and dual-sourcing strategies to preserve continuity of supply.
For health systems and ambulatory centers, the immediate implications included higher procurement costs for certain imported disposable devices, specialized endoscopes, and high-end imaging peripherals, which in some cases altered device selection criteria. In response, purchasing teams intensified negotiations around total cost of ownership, extended warranty arrangements, and bundled service agreements that could offset incremental tariff impacts. Clinicians and administrators also accelerated interest in devices that offered reduced operating-room time or lower disposables consumption per case to limit exposure to rising unit costs.
On the manufacturing side, tariff pressures encouraged process optimization and cost engineering efforts, including redesign of packaging, substitution of non-critical components sourced from lower-tariff jurisdictions, and strategic inventory pre-positioning. Regulatory compliance remained a non-negotiable constraint, so any rapid supplier switches required careful validation to maintain device performance and safety. The cumulative effect of the tariffs was not merely a price shock; it was a catalyst for structural adjustments across procurement, supply continuity planning, and product strategy that will influence stakeholder decisions well beyond the initial policy change.
In-depth segmentation analysis revealing how product types, clinical applications, end-user settings, distribution channels, and enabling technologies interact to shape adoption dynamics
Segmentation nuances are central to competitive positioning and go-to-market tactics within urology. Product differentiation spans disposable devices and reusable devices, with disposable offerings such as catheters and stents-where catheters break down into Foley and intermittent categories and stents include nephrostomy and ureteral variations-competing against reusable endoscopes and surgical instruments, the endoscopes themselves encompassing flexible and rigid formats. Each product pathway presents distinct clinical benefits, sterilization requirements, and procurement drivers, which influence adoption depending on care setting and case mix.
Application-focused segmentation further clarifies demand signals, covering indications from benign prostatic hyperplasia treatment and cancer diagnosis to stone removal and urinary incontinence management. These applications dictate device functionality, imaging integration needs, and procedural volumes, shaping how vendors prioritize product investments. End-user differentiation across ambulatory surgical centers, clinics, and hospitals changes decision cycles and purchase authority, as ambulatory settings often prioritize disposability and ease of use, while hospitals may emphasize reusability and lifecycle cost optimization.
Distribution channels-including e-commerce platforms, hospital purchasing systems, and retail pharmacies-mediate access and influence pricing transparency and procurement agility. Technology segmentation is equally pivotal; imaging and laser technologies serve as key enabling categories, with imaging further divided into CT scan, MRI, and ultrasound modalities. The interplay of technology with device form factor determines clinical workflows and training requirements, meaning vendors must align commercial models with the technical expectations of each end-user segment to achieve sustainable adoption.
Regional insights that identify how regulatory nuances, reimbursement frameworks, and care delivery models across major geographies drive differentiated adoption and market access strategies
Regional dynamics exert a pronounced influence on regulatory pathways, reimbursement environments, and clinical practice patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidation among health systems, an emphasis on outpatient expansion, and focused investment in diagnostics and minimally invasive therapies drive demand for integrated device-imaging solutions and single-use technologies that support patient throughput. Payment models and accreditation standards in this region also heighten the need for demonstrable clinical and economic value.
Europe, Middle East & Africa presents a heterogeneous landscape in which national reimbursement frameworks and local procurement rules create variable adoption rhythms. Regulatory harmonization efforts coexist with diverse clinical guidelines, so manufacturers must pursue region-specific evidence generation and market access strategies. In contrast, Asia-Pacific is characterized by rapid infrastructure investment, growing procedural volumes, and an expanding private-sector care segment; these factors increase receptivity to novel technologies, while also elevating price sensitivity and the importance of scalable service networks.
Across all regions, the convergence of aging populations and increasing prevalence of urological conditions informs long-term clinical demand, but local supply chain resilience, regulatory timing, and reimbursement pathways ultimately determine the pace and shape of technology uptake. For global vendors, regional strategies must balance standardized platforms with tailored market-access plans that reflect local clinical practice and procurement realities.
Corporate competitive landscape analysis emphasizing innovation, partnerships, service excellence, and strategic M&A that determine leadership in the urology device ecosystem
Competitive dynamics in urology device markets are driven by product innovation, clinical evidence, and integrated service offerings. Leading firms concentrate investment in imaging-enabled devices and procedural platforms that reduce operative time and enhance diagnostic yield, while newer entrants typically focus on single-use disposables and modular technologies that lower barriers to entry for outpatient settings. Strategic partnerships between device manufacturers, imaging providers, and software vendors have emerged to deliver bundled solutions that address both clinical outcomes and workflow optimization.
Key companies differentiate through clinical training programs, robust post-market surveillance, and comprehensive service contracts that minimize downtime and reprocessing risk. Mergers and acquisitions continue to be a strategic lever for capability acquisition, particularly in areas like advanced imaging, laser systems, and disposable endoscope design. Intellectual property around tip optics, laser delivery, and biocompatible materials remains a competitive advantage, and firms that can combine that IP with scalable manufacturing and distribution capabilities secure stronger positioning with hospital systems and large group purchasing organizations.
Ultimately, the most successful companies align product roadmaps with real-world clinician needs, invest in high-quality evidence generation, and offer flexible commercial terms that reflect total cost-of-care considerations. This combination of clinical credibility and commercial pragmatism is increasingly decisive when procurement committees weigh competing solutions.
Actionable recommendations for manufacturers and healthcare providers to strengthen innovation pipelines, fortify supply chains, and optimize commercialization and clinical adoption strategies
Industry leaders must act decisively to translate current market signals into durable competitive advantage. First, manufacturers should prioritize modular product platforms that allow rapid adaptation to both disposable and reusable use cases, reducing time-to-market for incremental innovations and accommodating diverse end-user needs. Investing in robust clinical evidence and real-world data collection programs will strengthen value propositions for both hospitals and ambulatory centers, while facilitating smoother reimbursement discussions.
Second, supply chain resilience must be elevated to a strategic priority; near-shoring, dual sourcing, and inventory optimization strategies can mitigate tariff exposure and improve responsiveness. Third, companies should expand service and training capabilities to lower adoption friction, including virtual training modules and integrated maintenance agreements that address concerns around reprocessing and device uptime. Fourth, forging partnerships with imaging and software providers can produce bundled offerings that justify premium positioning based on workflow and outcome improvements.
Finally, commercial teams should adapt pricing and contracting models to account for end-user diversity, offering flexible bundles for ambulatory surgical centers and value-based arrangements for health systems. By aligning product design, evidence generation, and commercial strategy with clinical workflows and procurement realities, leaders can secure more sustainable adoption and stronger long-term relationships with customers.
Robust and transparent research methodology combining clinician interviews, technical literature synthesis, and device-level validation to ensure evidence-based insights and documented limitations
This research synthesizes primary stakeholder interviews, technical literature review, and systematic analysis of regulatory and clinical practice sources to build an evidence-driven understanding of the urology device landscape. Primary inputs included structured interviews with clinicians across hospital, ambulatory, and clinic settings, procurement professionals, and device engineers to capture operational realities, decision criteria, and unmet clinical needs. Secondary research encompassed peer-reviewed journals, technical standards, device labeling, and regulatory guidance to corroborate clinical pathways and technology characteristics.
Data integrity was maintained through cross-validation of qualitative inputs against published clinical evidence and device specifications. The analysis placed particular emphasis on technology interoperability, sterilization pathways, and imaging modality integration due to their outsized influence on adoption decisions. Where applicable, case studies illuminated how specific hospital systems or ambulatory networks implemented devices to achieve throughput and infection-control objectives. Methodological limitations were explicitly documented, including variable regional regulatory timelines and the heterogeneity of procurement practices, and these caveats were reflected in the interpretation of findings.
Concise concluding synthesis outlining how clinical, technological, and operational drivers converge to determine the future direction of urology device adoption and strategy
In conclusion, the urology device landscape is being reshaped by converging forces: a shift toward outpatient care, rapid imaging and laser technology advances, heightened attention to infection control, and evolving procurement dynamics influenced by trade policies and supply chain realities. Product design choices between disposable and reusable devices carry implications that extend beyond unit cost to encompass sterilization logistics, clinical workflow, and patient safety. These trade-offs will continue to guide clinician preference and institutional purchasing decisions.
Strategically, vendors and health systems that invest in clinical evidence, integrate imaging and device platforms, and adopt resilient sourcing strategies will be best positioned to capture sustained clinical adoption. Regional differences in regulation, reimbursement, and care models necessitate tailored approaches that blend global platform benefits with local execution. Stakeholders that act proactively to align product development, commercialization, and operational support with the real-world demands of clinicians and procurement teams will unlock the greatest value for patients and providers alike.
Please Note: PDF & Excel + Online Access - 1 Year
Contextual introduction describing how demographic trends, clinical demands, and technological advances are collectively redefining urology care pathways and procurement priorities
Urology practice and device innovation sit at the intersection of demographic pressure, technological evolution, and shifting care delivery models. Recent advances in imaging, minimally invasive instrumentation, and single-use device design have combined with rising procedural volumes to reshape clinical pathways, procurement priorities, and vendor strategies. Clinicians seek tools that improve patient outcomes while supporting faster throughput and lower perioperative risk, whereas procurement leaders prioritize device reliability, reprocessing efficiency, and cost predictability.
Against this backdrop, the landscape is further influenced by policy changes, supply chain restructuring, and evolving reimbursement frameworks that affect how hospitals, ambulatory surgical centers, and clinics evaluate new technologies. These dynamics create both risk and opportunity for manufacturers, distributors, and health systems. Understanding the nuanced interplay between device types, clinical applications, and technology enablers is critical for stakeholders preparing for near-term shifts and for those designing long-term portfolios that emphasize value-based care.
Comprehensive overview of the major structural changes reshaping urology including care-site migration, imaging advances, single-use adoption, and infection control priorities
The last several years have witnessed transformative shifts that have materially altered the urology landscape. First, the move toward ambulatory care and same-day procedures has elevated demand for devices and technologies that support shorter procedure times, reduced inpatient stays, and predictable outcomes. This trend has placed a premium on endoscopic ergonomics, single-use device reliability, and technologies that integrate seamlessly into outpatient workflows.
Second, imaging sophistication and image-guided interventions have progressed rapidly, enabling more precise diagnostics and targeted therapy. Innovations in CT, MRI, and ultrasound imaging are complemented by improved visualization in flexible and rigid endoscopes, which together enhance diagnostic clarity and procedural accuracy. Third, the rapid adoption of laser technology for stone removal and benign prostatic hyperplasia treatment has shifted procedural algorithms, reducing reliance on more invasive approaches and supporting faster recovery.
Finally, heightened attention to infection prevention, supply chain resilience, and lifecycle costs is driving re-evaluation of reusable versus disposable devices. Decision-makers increasingly weigh the clinical benefits of reusable endoscopes and instruments against the operational risks and costs associated with reprocessing, sterilization, and potential device downtime. Overall, these transformative shifts are creating a market environment in which clinical efficacy, operational efficiency, and risk mitigation converge as the primary determinants of adoption.
Strategic analysis of how the United States tariffs enacted in 2025 catalyzed sourcing realignment, procurement negotiation shifts, and supply chain resilience measures across urology stakeholders
The imposition of United States tariffs in 2025 introduced a new layer of complexity across global medical device supply chains and procurement strategies. Tariff-driven cost increases for imported components and finished devices compelled many manufacturers to re-evaluate sourcing footprints, reconsider supplier relationships, and, where feasible, shift assembly and final production closer to end markets. These adjustments affected lead times and inventory management practices, prompting increased reliance on safety stock and dual-sourcing strategies to preserve continuity of supply.
For health systems and ambulatory centers, the immediate implications included higher procurement costs for certain imported disposable devices, specialized endoscopes, and high-end imaging peripherals, which in some cases altered device selection criteria. In response, purchasing teams intensified negotiations around total cost of ownership, extended warranty arrangements, and bundled service agreements that could offset incremental tariff impacts. Clinicians and administrators also accelerated interest in devices that offered reduced operating-room time or lower disposables consumption per case to limit exposure to rising unit costs.
On the manufacturing side, tariff pressures encouraged process optimization and cost engineering efforts, including redesign of packaging, substitution of non-critical components sourced from lower-tariff jurisdictions, and strategic inventory pre-positioning. Regulatory compliance remained a non-negotiable constraint, so any rapid supplier switches required careful validation to maintain device performance and safety. The cumulative effect of the tariffs was not merely a price shock; it was a catalyst for structural adjustments across procurement, supply continuity planning, and product strategy that will influence stakeholder decisions well beyond the initial policy change.
In-depth segmentation analysis revealing how product types, clinical applications, end-user settings, distribution channels, and enabling technologies interact to shape adoption dynamics
Segmentation nuances are central to competitive positioning and go-to-market tactics within urology. Product differentiation spans disposable devices and reusable devices, with disposable offerings such as catheters and stents-where catheters break down into Foley and intermittent categories and stents include nephrostomy and ureteral variations-competing against reusable endoscopes and surgical instruments, the endoscopes themselves encompassing flexible and rigid formats. Each product pathway presents distinct clinical benefits, sterilization requirements, and procurement drivers, which influence adoption depending on care setting and case mix.
Application-focused segmentation further clarifies demand signals, covering indications from benign prostatic hyperplasia treatment and cancer diagnosis to stone removal and urinary incontinence management. These applications dictate device functionality, imaging integration needs, and procedural volumes, shaping how vendors prioritize product investments. End-user differentiation across ambulatory surgical centers, clinics, and hospitals changes decision cycles and purchase authority, as ambulatory settings often prioritize disposability and ease of use, while hospitals may emphasize reusability and lifecycle cost optimization.
Distribution channels-including e-commerce platforms, hospital purchasing systems, and retail pharmacies-mediate access and influence pricing transparency and procurement agility. Technology segmentation is equally pivotal; imaging and laser technologies serve as key enabling categories, with imaging further divided into CT scan, MRI, and ultrasound modalities. The interplay of technology with device form factor determines clinical workflows and training requirements, meaning vendors must align commercial models with the technical expectations of each end-user segment to achieve sustainable adoption.
Regional insights that identify how regulatory nuances, reimbursement frameworks, and care delivery models across major geographies drive differentiated adoption and market access strategies
Regional dynamics exert a pronounced influence on regulatory pathways, reimbursement environments, and clinical practice patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidation among health systems, an emphasis on outpatient expansion, and focused investment in diagnostics and minimally invasive therapies drive demand for integrated device-imaging solutions and single-use technologies that support patient throughput. Payment models and accreditation standards in this region also heighten the need for demonstrable clinical and economic value.
Europe, Middle East & Africa presents a heterogeneous landscape in which national reimbursement frameworks and local procurement rules create variable adoption rhythms. Regulatory harmonization efforts coexist with diverse clinical guidelines, so manufacturers must pursue region-specific evidence generation and market access strategies. In contrast, Asia-Pacific is characterized by rapid infrastructure investment, growing procedural volumes, and an expanding private-sector care segment; these factors increase receptivity to novel technologies, while also elevating price sensitivity and the importance of scalable service networks.
Across all regions, the convergence of aging populations and increasing prevalence of urological conditions informs long-term clinical demand, but local supply chain resilience, regulatory timing, and reimbursement pathways ultimately determine the pace and shape of technology uptake. For global vendors, regional strategies must balance standardized platforms with tailored market-access plans that reflect local clinical practice and procurement realities.
Corporate competitive landscape analysis emphasizing innovation, partnerships, service excellence, and strategic M&A that determine leadership in the urology device ecosystem
Competitive dynamics in urology device markets are driven by product innovation, clinical evidence, and integrated service offerings. Leading firms concentrate investment in imaging-enabled devices and procedural platforms that reduce operative time and enhance diagnostic yield, while newer entrants typically focus on single-use disposables and modular technologies that lower barriers to entry for outpatient settings. Strategic partnerships between device manufacturers, imaging providers, and software vendors have emerged to deliver bundled solutions that address both clinical outcomes and workflow optimization.
Key companies differentiate through clinical training programs, robust post-market surveillance, and comprehensive service contracts that minimize downtime and reprocessing risk. Mergers and acquisitions continue to be a strategic lever for capability acquisition, particularly in areas like advanced imaging, laser systems, and disposable endoscope design. Intellectual property around tip optics, laser delivery, and biocompatible materials remains a competitive advantage, and firms that can combine that IP with scalable manufacturing and distribution capabilities secure stronger positioning with hospital systems and large group purchasing organizations.
Ultimately, the most successful companies align product roadmaps with real-world clinician needs, invest in high-quality evidence generation, and offer flexible commercial terms that reflect total cost-of-care considerations. This combination of clinical credibility and commercial pragmatism is increasingly decisive when procurement committees weigh competing solutions.
Actionable recommendations for manufacturers and healthcare providers to strengthen innovation pipelines, fortify supply chains, and optimize commercialization and clinical adoption strategies
Industry leaders must act decisively to translate current market signals into durable competitive advantage. First, manufacturers should prioritize modular product platforms that allow rapid adaptation to both disposable and reusable use cases, reducing time-to-market for incremental innovations and accommodating diverse end-user needs. Investing in robust clinical evidence and real-world data collection programs will strengthen value propositions for both hospitals and ambulatory centers, while facilitating smoother reimbursement discussions.
Second, supply chain resilience must be elevated to a strategic priority; near-shoring, dual sourcing, and inventory optimization strategies can mitigate tariff exposure and improve responsiveness. Third, companies should expand service and training capabilities to lower adoption friction, including virtual training modules and integrated maintenance agreements that address concerns around reprocessing and device uptime. Fourth, forging partnerships with imaging and software providers can produce bundled offerings that justify premium positioning based on workflow and outcome improvements.
Finally, commercial teams should adapt pricing and contracting models to account for end-user diversity, offering flexible bundles for ambulatory surgical centers and value-based arrangements for health systems. By aligning product design, evidence generation, and commercial strategy with clinical workflows and procurement realities, leaders can secure more sustainable adoption and stronger long-term relationships with customers.
Robust and transparent research methodology combining clinician interviews, technical literature synthesis, and device-level validation to ensure evidence-based insights and documented limitations
This research synthesizes primary stakeholder interviews, technical literature review, and systematic analysis of regulatory and clinical practice sources to build an evidence-driven understanding of the urology device landscape. Primary inputs included structured interviews with clinicians across hospital, ambulatory, and clinic settings, procurement professionals, and device engineers to capture operational realities, decision criteria, and unmet clinical needs. Secondary research encompassed peer-reviewed journals, technical standards, device labeling, and regulatory guidance to corroborate clinical pathways and technology characteristics.
Data integrity was maintained through cross-validation of qualitative inputs against published clinical evidence and device specifications. The analysis placed particular emphasis on technology interoperability, sterilization pathways, and imaging modality integration due to their outsized influence on adoption decisions. Where applicable, case studies illuminated how specific hospital systems or ambulatory networks implemented devices to achieve throughput and infection-control objectives. Methodological limitations were explicitly documented, including variable regional regulatory timelines and the heterogeneity of procurement practices, and these caveats were reflected in the interpretation of findings.
Concise concluding synthesis outlining how clinical, technological, and operational drivers converge to determine the future direction of urology device adoption and strategy
In conclusion, the urology device landscape is being reshaped by converging forces: a shift toward outpatient care, rapid imaging and laser technology advances, heightened attention to infection control, and evolving procurement dynamics influenced by trade policies and supply chain realities. Product design choices between disposable and reusable devices carry implications that extend beyond unit cost to encompass sterilization logistics, clinical workflow, and patient safety. These trade-offs will continue to guide clinician preference and institutional purchasing decisions.
Strategically, vendors and health systems that invest in clinical evidence, integrate imaging and device platforms, and adopt resilient sourcing strategies will be best positioned to capture sustained clinical adoption. Regional differences in regulation, reimbursement, and care models necessitate tailored approaches that blend global platform benefits with local execution. Stakeholders that act proactively to align product development, commercialization, and operational support with the real-world demands of clinicians and procurement teams will unlock the greatest value for patients and providers alike.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
197 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rise of robotic-assisted laparoscopic surgeries for prostate and kidney procedures driven by technological advances and patient demand
- 5.2. Development and adoption of non-invasive biomarkers for early detection of prostate cancer to improve patient outcomes
- 5.3. Growth in minimally invasive therapies for benign prostatic hyperplasia like prostate artery embolization and water vapor therapy
- 5.4. Integration of telemedicine and remote patient monitoring platforms for post-surgical care in urology practices across regions
- 5.5. Surge in targeted therapies and immunotherapy combinations for advanced urothelial carcinoma based on precision medicine approaches
- 5.6. Adoption of AI-powered diagnostic imaging analysis to enhance accuracy and efficiency in urologic disease detection
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Urology Market, by Product Type
- 8.1. Disposable Devices
- 8.1.1. Catheters
- 8.1.1.1. Foley Catheters
- 8.1.1.2. Intermittent Catheters
- 8.1.2. Stents
- 8.1.2.1. Nephrostomy Stents
- 8.1.2.2. Ureteral Stents
- 8.2. Reusable Devices
- 8.2.1. Endoscopes
- 8.2.1.1. Flexible Endoscopes
- 8.2.1.2. Rigid Endoscopes
- 8.2.2. Surgical Instruments
- 9. Urology Market, by Application
- 9.1. Benign Prostatic Hyperplasia Treatment
- 9.2. Cancer Diagnosis
- 9.3. Stone Removal
- 9.4. Urinary Incontinence Management
- 10. Urology Market, by End User
- 10.1. Ambulatory Surgical Centers
- 10.2. Clinics
- 10.3. Hospitals
- 11. Urology Market, by Distribution Channel
- 11.1. E-Commerce
- 11.2. Hospital Purchases
- 11.3. Retail Pharmacies
- 12. Urology Market, by Technology
- 12.1. Imaging Technology
- 12.1.1. CT Scan
- 12.1.2. MRI
- 12.1.3. Ultrasound
- 12.2. Laser Technology
- 13. Urology Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Urology Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Urology Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Boston Scientific Corporation
- 16.3.2. Medtronic plc
- 16.3.3. Johnson & Johnson
- 16.3.4. Stryker Corporation
- 16.3.5. Cook Group Incorporated
- 16.3.6. Olympus Corporation
- 16.3.7. Karl Storz SE & Co. KG
- 16.3.8. Richard Wolf GmbH
- 16.3.9. Siemens Healthineers AG
- 16.3.10. Fujifilm Holdings Corporation
- 16.3.11. Becton, Dickinson and Company
- 16.3.12. Teleflex Incorporated
- 16.3.13. CONMED Corporation
- 16.3.14. Coloplast Group
- 16.3.15. Dornier MedTech GmbH
- 16.3.16. Intuitive Surgical, Inc.
- 16.3.17. Procept BioRobotics Corporation
- 16.3.18. UroViu Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
